BMS-986507 Combinations for Lung Cancer

Recruiting in Palo Alto (17 mi)

+22 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Recruiting

Sponsor: Bristol-Myers Squibb

Disqualifiers: CNS metastases, Heart disease, others

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Do I need to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Eligibility Criteria

This trial is for adults with advanced solid tumors, which can include various types of cancer that have spread beyond their original location. Specific eligibility details are not provided, but typically participants must meet certain health standards and may need to have tried other treatments first.

Inclusion Criteria

I am fully active or restricted in physically strenuous activity but can do light work.

Participants must have at least one measurable lesion per response evaluation criteria in solid tumors

Participants must have a life expectancy of at least 3 months at the time of the first dose

Exclusion Criteria

My lung cancer is not a mix of SCLC and NSCLC types.

Other protocol-defined Inclusion/Exclusion criteria apply

I do not have a history of severe heart disease.

See 2 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive BMS-986507 combinations to evaluate safety, tolerability, drug levels, and preliminary efficacy

8-12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

BMS-986507 (Other)

Trial OverviewThe study is testing the safety and effectiveness of combining a new drug called BMS-986507 with Osimertinib and Pembrolizumab in treating advanced cancers. It will look at how well patients tolerate the combination therapy and measure its impact on their tumors.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Group BExperimental Treatment2 Interventions

Group II: Group AExperimental Treatment2 Interventions